
Precision drug + diagnostics biotech scores modest Series A, retrofitting existing drug for new indication
A small biotech is going after sepsis — and it has raised some more money to advance that goal and get its newly-acquired drug into the clinic.
With $52 million in debt and equity funds via a Series A, precision therapeutics outfit Endpoint Health (no relation to Endpoints News) now has the capital to also consider expanding into autoimmune indications, CEO Jason Springs tells Endpoints News.
The funds will push the biotech’s platform and pipeline forward, plus move the startup’s in-licensed drug to Phase II clinical trials and submit an IND and IDE (Investigational Device Exemption) to the FDA later in 2022, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.